Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$11.3M
12M shares
52-week range
$0.81 – $4.19
5% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
29.58%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $138.0K | $21.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $4.3M | $0 | $3.7M | $8.9M | $7.0M | $6.3M | $3.6M | $0 |
| Gross profit | −$4.2M | $21.0K | −$3.7M | −$8.9M | −$7.0M | −$6.3M | −$3.6M | $0 |
| Gross margin | -3034.8% | 100.0% | — | — | — | — | — | — |
| R&D | $4.3M | $4.3M | $3.7M | $8.9M | $7.0M | $6.3M | $3.6M | $4.6M |
| Operating income | −$7.4M | −$9.0M | −$8.8M | −$13.5M | −$11.5M | −$10.8M | −$7.4M | −$9.2M |
| EBITDA | −$7.3M | −$8.9M | −$8.7M | −$13.2M | −$11.4M | −$10.6M | −$7.1M | −$8.7M |
| Net income | −$7.4M | −$8.9M | −$8.8M | −$13.3M | −$11.5M | −$10.8M | −$7.2M | −$8.7M |
| Net margin | -5333.3% | -42419.0% | — | — | — | — | — | — |
| EPS (diluted) | -6218.35 | -2074.18 | -207.25 | -111.32 | -89.61 | -46.76 | -0.91 | -1.45 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-1.38 | $-1.39–$-1.35 | 2 |
| 2027 | $0 | $-0.86 | $-1.02–$-0.70 | 2 |
Forward consensus · source: Financial Modeling Prep
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
www.phiopharma.comNo one on the platform currently holds PHIO.
No tracked institution reports a position in PHIO as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-07-05 | 1-for-9reverse |
| 2023-01-26 | 1-for-12reverse |
| 2020-01-15 | 1-for-55reverse |
| 2018-01-08 | 1-for-10reverse |
| 2016-04-18 | 1-for-10reverse |
No one on the platform has traded PHIO yet.
| $7M |
| — |
| CELZCreative Medical Technology Holdings, Inc. | $0.81 | -32.48% | $2M | — |
| GLTODamora Therapeutics, Inc. | $21.58 | -3.36% | $34M | — |
Source: Financial Modeling Prep · peers by sector/industry
$PHIO CEO purchased 10,000 shares at $0.99 for a total of $9,900. Bitterman Robert J now owns 421,421 shares. https://ceo-buys.com
View on StockTwits ↗$PHIO look at the date 2022. This guy has been posting for 4 years and beyond about this stock. Either you’re obsessed or lost your life savings. Just pathetic. Move on dude. We get you’re bearish 😩🤡 @DosGatos
View on StockTwits ↗Small-Caps with Catalysts this week: 👇👇 ( $PHIO, $SXTP, $PSEC, $IBO, $LHAI, etc...) #NASDAQ #NYSE
View on StockTwits ↗$PHIO where is phio going from here? A little worried now since it's under 1.00 Already down 50% Like to see some progress
View on StockTwits ↗@trader_23 @jwdnl33 @DosGatos truthfully and was n RXII and he’s just trying to save you. Unless they changed their RNA platform it was a mix of sdRNAI as an oligonuleotide for scarring as RXII . Geert stepped down and took same tech for cancer now, he like me and many others were scammed $PHIO . But I hope it’s different and you guys make money. He’s just trying to help
View on StockTwits ↗@lgb2 $TPST I put Brady as the best con ceo of all time up there with Geert c from $PHIO when it was RXII going for scarring
View on StockTwits ↗$PHIO lol oh yea! Virtual Non-Deal Roadshow! That’ll get em!
View on StockTwits ↗https://nfne.ws/302784 $PHIO @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #Healt
View on StockTwits ↗$PHIO https://finance.yahoo.com/healthcare/articles/phio-pharmaceuticals-announces-sirna-therapy-110000386.html
View on StockTwits ↗$PHIO https://finance.yahoo.com/healthcare/articles/phio-pharmaceuticals-reaches-key-milestone-110000133.html
View on StockTwits ↗$PHIO Strong close - what are we thinking here 7 for 1?
View on StockTwits ↗$PHIO Clearing the runway:) There will be absolutely no interference when the coil is released. Like Jamie Fox said, “Don’t Be Scured” lol
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.